11 results about "Ketorolac" patented technology

The present invention relates to an ophthalmic composition in the form of an aqueous solution containing levofloxacin or salt or derivative thereof and ketorolac or salt or derivative. The present invention relates to an ophthalmic composition in the form of an aqueous solution containing levofloxacin or salt or derivative thereof and ketorolac or salt or derivative thereof, for use in a method for the treatment of conjunctivitis and for the prevention or treatment of inflammation or prevention of infection after cataract surgery in a subject, according to a dosage regimen that improves patient compliance and tolerability and enables the prevention and treatment of intermediate / antibiotic-resistant infections.

The present disclosure describes topical ketorolac compositions that comprise a eutectic solvent, such as choline chloride and propylene glycol, and methods and uses thereof. The compositions of the present disclosure are capable of delivering an effective amount of ketorolac through the skin and are believed to be useful in treating inflammation and / or pain, such as gout.

The present invention relates to a pharmaceutical composition for use in the treatment of both low-grade and high-grade glioblastoma in a human subject. The composition comprises a synergistic combination of the following active agents: R-Ketorolac, Bumetanide, and Niflumic acid. This specific combination is designed to exert a synergistic therapeutic effect against glioblastoma by targeting multiple molecular pathways involved in tumor progression, inflammation, and ion transport. In a further aspect of the invention, there is provided a method for selecting a subpopulation of glioblastoma subjects who are responsive to the aforementioned treatment. This method comprises identifying genetic profiles predictive of a favorable therapeutic response to the combined administration of R-Ketorolac, Bumetanide, and Niflumic acid.

Provided are a method for preparing (R)-ketorolac and use thereof. The method includes the following steps: step 1, preparing ketorolac; and step 2, subjecting the ketorolac to resolution to obtain the (R)-ketorolac, the resolution being selected from the group consisting of chiral amine resolution and enzyme resolution.

A ketorolaco derivative as shown in formula (I) has a better half-life and stability, has good pharmacokinetic properties, and has a higher stability in vitro; and as a preparation, the ketorolaco derivative can enhance efficacy and reduce toxicity. The present invention well improves the defects of frequent administration, gastrointestinal side effects, poor compliance and the like in traditional ketorolaco preparations.

The present invention relates to a storage-stable pharmaceutical composition for ophthalmic administration in the form of an aqueous solution comprising a therapeutically effective amount of antibiotic levofloxacin or a pharmaceutically acceptable salt or derivative thereof, as a first active ingredient, and a therapeutically effective amount of non-steroidal anti-inflammatory and analgesic ketorolac or a pharmaceutically acceptable salt or derivative thereof, as a second active ingredient, wherein said first active ingredient is from about 0.4 to about 0.9% w / v and said second active ingredient is from about 0.4 to about 0.9% w / v, wherein the weight / volume percentages are expressed as g / 100mL units, in order to prevent the precipitation and improve the stability of the product.

The present application belongs to the technical field of medicine crystallization, and particularly relates to a ketorolac and piperazine co-crystal crystal form and a preparation method thereof. The co-crystal has characteristic peaks at 8.0+ / -0.2°, 9.8+ / -0.2°, 13.5+ / -0.2°, 16.1+ / -0.2°, 17.0+ / -0.2°, 18.3+ / -0.2°, 19.5+ / -0.2°, 19.6+ / -0.2°, 19.9+ / -0.2° and 28.7+ / -0.2° in an X-ray diffraction spectrum expressed in 2θ using Cu-Kα radiation. The co-crystal preparation process is simple, the process is easy to control, the stability is good, the solubility of ketorolac in water is significantly improved, and under the condition of the same prescription, the tablet prepared by taking the co-crystal as an active ingredient has a faster dissolution rate and a higher dissolution degree, and is more suitable for being made into an oral preparation.

The invention provides an aqueous liquid composition for ophthalmic administration, comprising therapeutically effective amounts of a ketorolac compound and of a corticosteroid, wherein the ketorolac compound is present in an essentially dissolved form; wherein the corticosteroid is present in the form of suspended particles; and wherein the composition exhibits an acidic pH of about 6.5 or less. The invention further provides compositions as disclosed herein for use in the prevention or treatment of ocular inflammation and methods for preventing or treating ocular inflammation in a subject.

This invention belongs to the field of pharmaceutical synthesis technology, specifically relating to a method for synthesizing a key intermediate of ketorolac. The method involves reacting 2-benzoylpyrrole with triethyl methanetricarboxylate in the presence of tert-butanol peroxide, potassium iodide, cuprous iodide, and tetrabutylammonium iodide, followed by post-treatment to yield 5-benzoylpyrrole-2-methanetricarboxylate triethyl ester (M-1). The reaction conditions are mild, the operation is simple, the reaction steps are few, and the product yield and purity are high, making it suitable for industrial-scale production. It avoids the problem of large amounts of manganese ions and acetic acid present in the system in existing technologies.

Provided are a method for preparing (R)-ketorolac and use thereof, belonging to the technical field of organic synthesis. The method includes the following steps: step 1, preparing ketorolac; and step 2, subjecting the ketorolac to resolution to obtain the (R)-ketorolac, the resolution being selected from the group consisting of chiral amine resolution and enzyme resolution. In the disclosure, glacial acetic acid is used as a reaction solvent, which is not only clean and environmental-friendly, but also easy to be removed. The glacial acetic acid could significantly improve a conversion rate of SM1 as a raw material, thereby improving the yield and the purity of the ketorolac, such that the ketorolac has a yield of not less than 70% and a purity of not less than 99%. The ketorolac is subjected to chiral resolution by the chiral amine or the enzyme to obtain the (R)-ketorolac with a high purity and a high yield, and the (R)-ketorolac could prevent chemotherapy resistance and improve both chemotherapeutic efficacy and cure rate.